DE60230017D1 - Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen - Google Patents

Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen

Info

Publication number
DE60230017D1
DE60230017D1 DE60230017T DE60230017T DE60230017D1 DE 60230017 D1 DE60230017 D1 DE 60230017D1 DE 60230017 T DE60230017 T DE 60230017T DE 60230017 T DE60230017 T DE 60230017T DE 60230017 D1 DE60230017 D1 DE 60230017D1
Authority
DE
Germany
Prior art keywords
orote
hemmer
combination
protein transferase
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60230017T
Other languages
English (en)
Inventor
David William End
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Application granted granted Critical
Publication of DE60230017D1 publication Critical patent/DE60230017D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE60230017T 2001-02-15 2002-02-06 Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen Expired - Lifetime DE60230017D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26883901P 2001-02-15 2001-02-15
PCT/EP2002/001248 WO2002064142A1 (en) 2001-02-15 2002-02-06 Farnesyl protein transferase inhibitor combinations with antiestrogen agents

Publications (1)

Publication Number Publication Date
DE60230017D1 true DE60230017D1 (de) 2009-01-08

Family

ID=23024710

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60230017T Expired - Lifetime DE60230017D1 (de) 2001-02-15 2002-02-06 Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen

Country Status (7)

Country Link
US (4) US20040110769A1 (de)
EP (1) EP1365763B1 (de)
JP (2) JP4969016B2 (de)
AT (1) ATE415161T1 (de)
DE (1) DE60230017D1 (de)
ES (1) ES2318000T3 (de)
WO (1) WO2002064142A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
US20060035875A1 (en) * 2002-10-09 2006-02-16 Yukimasa Shiotsu Remedy for hormone-dependent cancer
EP1552020B1 (de) * 2002-10-18 2012-02-29 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Lmna-gen und seine beteiligung an progeria hutchinson-gilford (hgps) und arteriosklerose
US7838531B2 (en) 2002-10-18 2010-11-23 The United States Of America As Represented By The Department Of Health And Human Services Farnesyltransferase inhibitors for treatment of laminopathies, cellular aging and atherosclerosis
WO2005046691A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl tranferase inhibitor with an antihormonal agent for the treatment of breast cancer
CA2634598A1 (en) 2005-12-23 2007-07-05 Link Medicine Corporation Treatment of synucleinopathies
BR112015008515A2 (pt) 2012-10-16 2017-07-04 Janssen Pharmaceutica Nv moduladores de ror t de quinolinila ligada à heteroarila
WO2014062658A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EP2909193B1 (de) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenylgebundene chinolinylmodulatoren von ror-gamma-t
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
KR20160070133A (ko) 2013-10-15 2016-06-17 얀센 파마슈티카 엔.브이. RORyt의 알킬 결합 퀴놀리닐 조절제
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
KR20160068956A (ko) 2013-10-15 2016-06-15 얀센 파마슈티카 엔.브이. RORyT의 퀴놀리닐 조절제
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
PL3137078T3 (pl) * 2014-05-01 2019-08-30 Eiger Biopharmaceuticals, Inc. Leczenie zakażenia wirusem zapalenia wątroby typu delta
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
HUE049620T2 (hu) 2015-08-17 2020-09-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
ES2863730T3 (es) 2016-11-03 2021-10-11 Kura Oncology Inc Inhibidores de la farnesiltransferasa para uso en el tratamiento del cáncer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3157882B2 (ja) * 1991-11-15 2001-04-16 帝国臓器製薬株式会社 新規なベンゾチオフエン誘導体
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2231105C (en) * 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
WO1999008682A1 (en) * 1997-08-15 1999-02-25 Duke University A method of preventing or treating estrogen-dependent diseases and disorders
CO5080764A1 (es) * 1997-12-22 2001-09-25 Schering Corp Metodos para el tratamiento de enfermedades proliferativas
DE19826213A1 (de) * 1998-06-09 1999-12-16 Schering Ag Neue Antiestrogene, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
AU1230100A (en) * 1998-10-29 2000-05-22 Merck & Co., Inc. A method of treating endometriosis
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
ES2262626T3 (es) * 2000-02-04 2006-12-01 Janssen Pharmaceutica N.V. Inhibidores de farnesil proteina transferasa para tratar cancer de mama.
CA2397558A1 (en) * 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
WO2002024683A1 (en) * 2000-09-25 2002-03-28 Janssen Pharmaceutica N.V. Farnesyl transferase inhibiting 6-[(substituted phenyl)methyl]-quinoline and quinazoline derivatives
ATE415161T1 (de) * 2001-02-15 2008-12-15 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen

Also Published As

Publication number Publication date
JP2010047589A (ja) 2010-03-04
US20110105557A1 (en) 2011-05-05
US20090023776A1 (en) 2009-01-22
ATE415161T1 (de) 2008-12-15
US20040110769A1 (en) 2004-06-10
JP4865027B2 (ja) 2012-02-01
EP1365763B1 (de) 2008-11-26
WO2002064142A1 (en) 2002-08-22
US20120108634A1 (en) 2012-05-03
JP2004517960A (ja) 2004-06-17
EP1365763A1 (de) 2003-12-03
JP4969016B2 (ja) 2012-07-04
ES2318000T3 (es) 2009-05-01

Similar Documents

Publication Publication Date Title
DE60230017D1 (de) Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
WO2001064226A3 (en) Farnesyl protein transferase inhibitor combinations with platinum compounds
WO2001064246A3 (en) Farnesyl protein transferase inhibitor combinations with an her2 antibody
WO2001064194A3 (en) Farnesyl protein transferase inhibitor combinations with camptothecin compounds
WO2001064252A3 (en) Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
EA200801301A1 (ru) ИНГИБИТОРЫ АКТИВНОСТИ Akt
BR0009670A (pt) Métodos de induzir morte de células de câncer e regressão de tumor
MY117961A (en) Inhibitors of farnesyl protein transferase
JO2305B1 (en) Gels extracted from wood
EA200800006A1 (ru) Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i
ATE415979T1 (de) Behandlung mit anti-erbb2 antikörpern
ATE355079T1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
MY133403A (en) Tetracycline derivatives and methods of use thereof
BR0208373A (pt) Inibidores da tirosina cinase
ECSP055537A (es) Monoclorhidrato de 2,5-diona-3-(1-metil-1h-indol-3-il)-4-[1-(piridin-2-ilmetil)piperidin-4-il]-1h-indol-3-il]-1h-pirrol cristalino
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
WO2001064218A3 (en) Farnesyl protein transferase inhibitor combinations
ATE419253T1 (de) Inhibitoren von thienopyridin- und furopyridinkinase
WO2001064217A3 (en) Combinations of a farnesyl protein transferase inhibitor with nitrogen mustard or nitrosourea alkylating agents
ATE253062T1 (de) 4- und 5-alkynyloxindole sowie 4- und 5- alkenyloxindole
MXPA03006224A (es) Inhibidores de cruzipaina y otras proteasas de cisteina.
EA200400235A1 (ru) Комбинированная терапия для лечения рака
WO2001064195A3 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor nucleoside derivatives
NO20031531L (no) Fremgangsmater for induksjon av kreftcelledod og tumorregresjon

Legal Events

Date Code Title Description
8364 No opposition during term of opposition